Skip to main content

Table 8 Mean and median survival as calculated from Kaplan-Meier survival curves. Only IBM which gives statistical significance as demonstrated by the univariate analysis in Table 7 is included in this table

From: Leveraging hybrid biomarkers in clinical endpoint prediction

Biomarkers 5-Year Overall Survival
Mean 95% CI Difference Median 95% CI Difference
Solid Composition
RDC
 SD 5.20 4.27–2.57 2.04 4.43 2.93–5.48 1.17
 NSD 3.16 2.57–3.74 3.26 2.49–3.90
LoFAR
 SD 5.50 4.46–6.61 2.23 5.20 3.11–5.24 2.00
 NSD 3.27 2.75–3.79 3.20 2.71–3.84
Solidity
 SD 4.96 4.08–5.85 1.64 3.90 2.85–5.48 0.58
 NSD 3.32 2.68–3.96 3.32 3.15–3.84
Lucent Composition
RLC
 SD 5.20 4.27–2.57 2.04 4.43 2.93–5.48 1.17
 NSD 3.16 2.57–3.74 3.26 2.49–3.90
ATR
 SD 5.05 4.11–5.99 1.69 3.78 2.76–5.48 0.46
 NSD 3.36 2.82–3.90 3.32 3.15–3.90
LoCAR
 SD 5.17 4.24–6.11 2.03 3.99 3.32–5.48 0.83
 NSD 3.14 2.59–3.69 3.16 2.49–3.84
  1. Data are presented in years